Date: 10/22/2025

"We're thrilled to announce positive preclinical data for our ATR-01 program during BIO-EUROPE as we advance towards a first-in-human clinical trial in ichthyosis vulgaris," Salva said. "Ichthyosis vulgaris is an autosomal semidominant genetic disorder that impacts approximately 1.3 million in the U.S. who have no treatment options beyond symptom management. Read more here https://www.dermatologytimes.com/view/azitra-s-atr-01-shows-promise-in-preclinical-studies-for-ichthyosis-vulgaris?utm_content=352377140&utm_medium=social&utm_source=linkedin&hss_channel=lcp-3680540